Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1

Antiviral Research

Volumn 93, Issue 2, 2012, Pages 239-244

  Huang, Chung Feng ^a   Yeh, Ming Lun ^a   Huang, Jee Fu ^a,b,c   Yang, Jeng Fu ^a   Hsieh, Ming Yen ^a   Lin, Zu Yau ^a,b   Chen, Shinn Cherng ^a,b   Wang, Liang Yen ^a,b   Hsi, Edward ^a,b   Juo, Suh Hang Hank ^a,d   Dai, Chia Yen ^a,b   Chuang, Wan Long ^a,b   Yu, Ming Lung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CEVR; HCV 1; IL 28B; RVR; Treatment

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ADULT; ALLELE; ARTICLE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; KINETICS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; TAIWAN; TREATMENT OUTCOME;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 84862789303     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.12.002     Document Type: Article

References (46)

1. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., Buggisch P., Goeser T., Rasenack J., Pape G.R., Schmidt W.E., Kallinowski B., Klinker H., Spengler U., Martus P., Alshuth U., Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086-1097.
2. Bronowicki J.P., Ouzan D., Asselah T., Desmorat H., Zarski J.P., Foucher J., Bourlière M., Renou C., Tran A., Melin P., Hézode C., Chevalier M., Bouvier-Alias M., Chevaliez S., Montestruc F., Lonjon-Domanec I., Pawlotsky J.M. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006, 131:1040-1048.
3. Chayama K., Hayes C.N., Yoshioka K., Moriwaki H., Okanoue T., Sakisaka S., Takehara T., Oketani M., Toyota J., Izumi N., Hiasa Y., Matsumoto A., Nomura H., Seike M., Ueno Y., Yotsuyanagi H., Kumada H. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. Hepatol. Res. 2010, 40:1155-1167.
4. Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afdhal N., Brown R.S., Belle S.H., Hoofnagle J.H., Kleiner D.E., Howell C.D. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
5. Craxi A. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 2011, 55:245-264.
6. Dai C.Y., Chuang W.L., Lee L.P., Chen S.C., Hou N.J., Lin Z.Y., Hsieh M.Y., Hsieh M.Y., Wang L.Y., Chang W.Y., Yu M.L. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. J. Viral Hepat. 2006, 13:770-774.
7. Dai C.Y., Chuang W.L., Chang W.Y., Chen S.C., Lee L.P., Hsieh M.Y., Hou N.J., Lin Z.Y., Huang J.F., Hsieh M.Y., Wang L.Y., Yu M.L. Tumor necrosis factor-alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J. Infect. Dis. 2006, 193:98-101.
8. Dai C.Y., Huang J.F., Hsieh M.Y., Hou N.J., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Chuang W.L., Yu M.L. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol. 2009, 50:712-718.
9. Dai C.Y., Ho C.K., Huang J.F., Hsieh M.Y., Hou N.J., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Yu M.L., Chuang W.L. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J. Hepatol. 2010, 52:160-166.
10. Ferenci P., Laferl H., Scherzer T.M., Gschwantler M., Maieron A., Brunner H., Stauber R., Bischof M., Bauer B., Datz C., Löschenberger K., Formann E., Staufer K., Steindl-Munda P. Peginterferon alfa-2a and ribavirin for 24weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008, 135:451-458.
11. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
12. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
13. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
14. Hsu C.S., Hsu S.J., Chen H.C., Tseng T.C., Liu C.H., Niu W.F., Jeng J., Liu C.J., Lai M.Y., Chen P.J., Kao J.H., Chen D.S. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl. Acad. Sci. USA 2011, 108:3719-3724.
15. Huang C.F., Yang J.F., Huang J.F., Dai C.Y., Chiu C.F., Hou N.J., Hsieh M.Y., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Chuang W.L., Yu M.L. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J. Gastroenterol. Hepatol. 2010, 25:758-765.
16. Ito K., Higami K., Masaki N., Sugiyama M., Mukaide M., Saito H., Aoki Y., Sato Y., Imamura M., Murata K., Nomura H., Hige S., Adachi H., Hino K., Yatsuhashi H., Orito E., Kani S., Tanaka Y., Mizokami M. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J. Clin. Microbiol. 2011, 49:1853-1860.
17. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., Ferenci P., Ackrill A.M., Willems B. Early identification of HCV genotype 1 patients responding to 24weeks peginterferon alpha-2a (40kd)/ribavirin therapy. Hepatology 2006, 43:954-960.
18. Kamal S.M., El Kamary S.S., Shardell M.D., Hashem M., Ahmed I.N., Muhammadi M., Sayed K., Moustafa A., Hakem S.A., Ibrahiem A., Moniem M., Mansour H., Abdelaziz M. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007, 46:1732-1740.
19. Lin Z.H., Xin Y.N., Dong Q.J., Wang Q., Jiang X.J., Zhan S.H., Sun Y., Xuan S.Y. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011, 53:726-736.
20. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., Vinelli F., Scotto G., Bacca D., Annese M., Romano M., Zechini F., Sogari F., Spirito F., Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2005, 352:2609-2617.
21. Mangia A., Thompson A.J., Santoro R., Piazzolla V., Tillmann H.L., Patel K., Shianna K.V., Mottola L., Petruzzellis D., Bacca D., Carretta V., Minerva N., Goldstein D.B., McHutchison J.G. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827.
22. Mangia A., Thompson A.J., Santoro R., Piazzolla V., Copetti M., Minerva N., Petruzzellis D., Mottola L., Bacca D., McHutchison J.G. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011, 54:772-780.
23. Martinez S.M., Fernández-Varo G., González P., Sampson E., Bruguera M., Navasa M., Jiménez W., Sánchez-Tapias J.M., Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2011, 33:138-148.
24. McCarthy J.J., Li J.H., Thompson A., Suchindran S., Lao X.Q., Patel K., Tillmann H.L., Muir A.J., McHutchison J.G. Replicated association between an interleukin-28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138:2307-2314.
25. Ochi H., Maekawa T., Abe H., Hayashida Y., Nakano R., Imamura M., Hiraga N., Kawakami Y., Aimitsu S., Kao J.H., Kubo M., Tsunoda T., Kumada H., Nakamura Y., Hayes C.N., Chayama K. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations. J. Gen. Virol. 2011, 92:1071-1081.
26. Okamoto H., Tokita H., Sakamoto M., Horikita M., Kojima M., Iizuka H., Mishiro S. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J. Gen. Virol. 1993, 74:2385-2390.
27. Oze T., Hiramatsu N., Yakushijin T., Mochizuki K., Oshita M., Hagiwara H., Mita E., Ito T., Fukui H., Inui Y., Hijioka T., Inada M., Kaytayama K., Tamura S., Yoshihara H., Inoue A., Imai Y., Kato M., Miyagi T., Yoshida Y., Tatsumi T., Kiso S., Kanto T., Kasahara A., Takehara T., Hayashi N. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J. Hepatol. 2011, 54:604-611.
28. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
29. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trépo C., Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48weeks or for 24weeks versus interferon alpha2b plus placebo for 48weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
30. Poynard T., McHutchison J., Goodman Z., Ling M.H., Albrecht J. Is an " a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000, 31:211-218.
31. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Gunthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
32. Rodriguez-Torres M., Sulkowski M.S., Chung R.T., Hamzeh F.M., Jensen D.M. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J. Viral Hepat. 2010, 17:139-147.
33. Sarrazin C., Susser S., Doehring A., Lange C.M., Müller T., Schlecker C., Herrmann E., Lötsch J., Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 2011, 54:415-421.
34. Sezaki H., Suzuki F., Kawamura Y., Yatsuji H., Hosaka T., Akuta N., Kobayashi M., Suzuki Y., Saitoh S., Arase Y., Ikeda K., Miyakawa Y., Kumada H. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig. Dis. Sci. 2009, 54:1317-1324.
35. Stättermayer A.F., Stauber R., Hofer H., Rutter K., Beinhardt S., Scherzer T.M., Zinober K., Datz C., Maieron A., Dulic-Lakovic E., Kessler H.H., Steindl-Munda P., Strasser M., Krall C., Ferenci P. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2011, 9:344-350.
36. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Müller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
37. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
38. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R., Poordad F., Lawitz E.J., McCone J., Shiffman M.L., Galler G.W., Lee W.M., Reindollar R., King J.W., Kwo P.Y., Ghalib R.H., Freilich B., Nyberg L.M., Zeuzem S., Poynard T., Vock D.M., Pieper K.S., Patel K., Tillmann H.L., Noviello S., Koury K., Pedicone L.D., Brass C.A., Albrecht J.K., Goldstein D.B., McHutchison J.G. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology 2010, 139:120-129.
39. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., Lok A.S. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
40. Yang J.F., Lin C.I., Huang J.F., Dai C.Y., Lin W.Y., Ho C.K., Hsieh M.Y., Lee L.P., Ho N.J., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Yu M.L., Chuang W.L., Chang W.Y. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J. Med. Sci. 2010, 26:461-469.
41. Yu M.L., Chuang W.L. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009, 24:336-345.
42. Yu M.L., Lin S.M., Lee C.M., Dai C.Y., Chang W.Y., Chen S.C., Lee L.P., Lin Z.Y., Hsieh M.Y., Wang L.Y., Chuang W.L., Liaw Y.F. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006, 44:1086-1097.
43. Yu M.L., Chuang W.L., Dai C.Y., Lee L.P., Hsieh M.Y., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Tsai S.L., Kuo H.T. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl. Res. 2006, 148:120-127.
44. Yu M.L., Dai C.Y., Huang J.F., Hou N.J., Lee L.P., Hsieh M.Y., Chiu C.F., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Chuang W.L. A randomised study of peginterferon and ribavirin for 16 versus 24weeks in patients with genotype 2 chronic hepatitis C. Gut 2007, 56:553-559.
45. Yu M.L., Dai C.Y., Huang J.F., Chiu C.F., Yang Y.H., Hou N.J., Lee L.P., Hsieh M.Y., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Chuang W.L. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008, 47:1884-1893.
46. Yu M.L., Huang C.F., Huang J.F., Chang N.C., Yang J.F., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Li Y.N., Wu M.S., Dai C.Y., Hank Juo S.H., Chuang W.L. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53:7-13.